ITIF Search

Preserving U.S. Leadership in Biopharmaceutical Innovation

Preserving U.S. Leadership in Biopharmaceutical Innovation
Tuesday, March 5, 202412:00 PM to 1:30 PM EST
U.S. Capitol Visitor Center, SVC 203-02First Street NEWashington DC, 20510

Event Summary

U.S. leadership in advanced technology industries is never guaranteed. It takes ongoing stewardship from policymakers to ensure America provides the most globally competitive environment to support cutting-edge innovation. Unfortunately, policy lapses in recent decades have contributed to America losing its global competitiveness, market share, and high-skilled, high-value-added employment across a wide range of advanced technology industries, including semiconductors, telecommunications equipment, televisions, solar panels, and chemicals. Now we are at risk of compromising U.S. biopharmaceutical leadership, which has become increasingly imperiled by policies imposing price controls and weakening intellectual property rights (IPR), with measures such as COVID-19 waivers and proposals to expand Bayh-Dole march-in rights.

Watch now for an expert panel discussion as it releases a new report examining why the United States lost its lead in other advanced technology industries, and how policymakers can avoid repeating the same mistakes in the biopharmaceutical sector.


Stephen Ezell@sjezell
Vice President, Global Innovation Policy, and Director, Center for Life Sciences Innovation
Information Technology and Innovation Foundation
David Kappos
Cravath, Swaine & Moore LLP
Frank R.
Frank R. Lichtenberg
Cain Brothers & Company Professor of Healthcare Management in the Faculty of Business
Columbia University Graduate School of Business
Hon. Paul R.
Hon. Paul R. Michel
Chief Judge (ret.)
US Court of Appeals for the Federal Circuit
Richard Tillyer, Ph.D.
Global Head, Discovery, Product Development & Supply
Johnson & Johnson
Back to Top